Ruxolitinib is a JAK1/2 inhibitor that promotes vesicular stomatitis, herpes simplex, and measles viral replication in cell culture [70,71,72,73,74,75,76]. This evidence concerns the gene JAK1 and herpes simplex infectious disease.